Running title: Mitochondria possess alloantigenicity.
 The alloimmune response against mitochondria mismatched NT-ESCs is weaker than that against major histocompatibility complex (MHC)-mismatched cell grafts.
 The immune response is adaptive, directed against mitochondrial content, and amenable for tolerance induction.
eTOC Blurb
Mismatched mitochondria in SCNT-derived ESC grafts trigger immune rejection despite matching for the entire nuclear genome with the murine recipient.
In somatic cell nucleus transfer (SCNT), the nucleus of a somatic cell is transplanted into an enucleated oocyte (Noggle et al., 2011) . It has been envisioned that by this means, autologous pluripotent stem cells can be generated for specific patient-matched therapies. Embryonic stem cells by nuclear transfer (NT-ESCs) were first successfully generated from mice (Munsie et al., 2000) and primates (Byrne et al., 2007) . After substantial optimization of the SCNT technique, the derivation of NT-ESCs from human fetal fibroblasts (Tachibana et al., 2013) , and most recently, also from adult somatic cells (Chung et al., 2014; Yamada et al., 2014) was reported.
These latter studies suggest that age-associated changes in the nucleus donor cell are not necessarily an impediment to generating human NT-ESCs (Chung et al., 2014) . Furthermore, the differentiation of insulin-producing beta cells derived from NT-ESCs generated from a longstanding diabetic patient proved that specialized cell types that were lost in diseased patients could be re-established (Yamada et al., 2014) . Because NT-ESCs acquire healthy mitochondria from the selected oocyte donor, inherited or acquired mtDNA diseases are most amenable for correction using the SCNT technology (Tachibana et al., 2013) . The recent advancements in SCNT methodology have increased expectations for this approach to lead to human-assisted reproductive technologies (Cibelli, 2014) .
A so far underappreciated obstacle for clinical application of SCNT-derived cell therapy may be the immunogenicity of mismatched mitochondria in NT-ESCs. After transplantation of NT-ESCderived cells or tissue back into the nucleus donor, mismatched mtDNA-coded proteins may induce alloimmunity. We here show that allogeneic mitochondria in murine NT-ESCs may trigger an adaptive immune response that impairs the survival of NT-ESC grafts.
To assess mitochondria-specific alloantigenicity, transplantation studies with SCNT-derived murine NT-ESCs were conducted across defined immunological barriers. SCNT was performed as described earlier (Kirak et al., 2010) Figure S2A ). These two non-synonymous single nucleotide polymorphisms (SNPs) were therefore the only differences in the entire cellular DNA between donor cells and recipient. According to dbSNP (Sherry et al., 2001) , both variants are common in mouse. The affected loci are conserved among vertebrates ( Figure   S2B ) and for one of the two observed variants a human counterpart is described in dbSNP. haplotype and are therefore MHC-mismatched, but mitochondria-matched to the NT-ESCs. The severely immunodeficient NOD SCID strain was used as negative control, because it cannot mount any antigen-specific cellular immune response. The CBA (CBA/J; H2 k ) strain is both MHC and mitochondria mismatched to the NT-ESCs. mtDNA sequencing revealed identical mtDNA genomes for CBA and BALB/c, (not shown) as was previously reported in the context of mouse mtDNA phylogeny (Goios et al., 2007) . Therefore, besides the MHC differences, NT-ESC transplantations into BALB/c and CBA cross the same mitochondrial mismatch.
Previous studies on the immunogenicity of murine mitochondrial peptides were mostly restricted to cytotoxic T lymphocytes (CTLs) and MHC class Ia and Ib presentation (Dabhi and Lindahl, 1995 spot frequencies, showed a similar relation between the recipient strains ( Figure 1C ). There was also a surge in NT-ESC-specific IgM antibodies 5 days after immunization in B6 recipients, which was significantly stronger than those in BALB/c or BDF1 ( Figure 1D ). There were no NT-ESC-specific IgM antibodies in NOD SCID.
In an additional experiment, we could exclude that there were general differences among BALB/c, BDF1, and B6 in the degree of immune responsiveness ( Figure S2C ). Splenocytes of these three strains were unspecifically stimulated and ELISPOT assays demonstrated similar Th1 and Th2 activation. This result permits us to attribute the above ELISPOT results to the mismatched proteins.
To exclude methodological bias by the SCNT technique itself, isogeneic BALB/c ESCs (isoESCs) were generated using SCNT with BALB/c donors for both oocytes and nuclei ( Figure   1E ). Transplantation experiments were performed with fully nuclear DNA-and mtDNA-matched, isogeneic BALB/c recipients, MiHA-and mitochondria-mismatched BDF1, and MHC-and mitochondria-mismatched B6. There was negligible Th1 and Th2 activation in isogeneic BALB/c recipients ( Figure 1F and G). Between mitochondria-mismatched recipients, an additional MHC mismatch (B6) generated a significantly stronger Th1 activation than an additional MiHA mismatch (BDF1, Figure 1F ). Together, these results demonstrate that an isolated mitochondria mismatch is sufficient to initiate marked Th activation and NT-ESC-directed antibody production.
These immune responses are not caused by the SCNT technology itself. Second, an MHC mismatch causes a significantly stronger immune activation than a MiHA mismatch, both in the setting of additional mitochondrial match or mismatch. And third, the Th1 activation is additive for an MHC-and a mitochondria-mismatch.
Based on the results by Ishikawa (Ishikawa et al., 2010) , which assumed that the innate immunity was responsible for rejection of mitochondria-mismatched cell grafts, the T celldeficient nude mouse model was used to study the NK cell response. Figure 1H ). Our results show that there was no increase in NK cell-driven IFNγ ELISPOT frequency in response to NT-ESCs compared to isoESCs ( Figure 1I ). Also, the survival of cell grafts was similar for NT-ESCs and isoESCs and all animals formed teratomas, thus excluding relevant innate rejection processes ( Figure   1J -K). Importantly, the transplantation experiment by Ishikawa was specifically designed to be mismatched for the maternally transmitted mitochondrial antigen (Mta) previously described by Fischer Lindahl (Fischer Lindahl et al., 1980) . Our transplant setting avoids this incompatibility and, as a consequence, we did not observe relevant innate immunity-driven rejection.
Survival of NT-ESC grafts and teratoma development were assessed in the transplantation settings of Figure 1A . As expected, all NT-ESC transplants survived and formed teratomas in NOD SCID recipients ( Figure 2A ), whereas all grafts were rejected in fully mismatched CBAs ( Figure 2B ). The rather mild Th1 activation in MiHA-mismatched BDF1 still allowed for 90% teratoma development of rapidly-proliferating NT-ESC grafts ( Figure 2C ), whereas there was only 20% teratoma growth in MHC-mismatched B6 ( Figure 2D ). In mitochondria-mismatched BALB/c, teratomas developed in 60% of the recipients, but the tumor growth was markedly slowed ( Figure 2E ). Half of the tumors did not develop until day 50 to 90. Interestingly, there was a strong correlation between graft survival and Th1 activation in individual BALB/c animals ( Figure 2F ). Only BALB/c recipients with very low spot frequencies developed teratomas, whereas animals with at least moderate Th1 activation rejected their grafts. This further supports the notion of a T cell-mediated rejection process of mitochondria-mismatched grafts.
To confirm a mitochondrial location of the immunogenic peptides, mitochondria of NT-ESCs were separated from the remainder of the cell (cytosol) and splenocytes of NT-ESC-immunized BALB/c were re-stimulated in vitro with either mismatched mitochondria or isogeneic cytosol ( Figure 2G ). Only the mismatched mitochondria caused an IFNγ response, whereas the spot frequencies with the isogeneic cytosol fractions were low, similar to those of un-stimulated responder splenocytes ( Figure 2H ). Of note, the ELISPOT frequencies of the separated cell compartments were markedly lower than those involving whole cells. Although their precise presentation mechanism remains elusive, the detection of mitochondrial peptides in the context of MHC (Dabhi and Lindahl, 1995; Duvvuri et al., 2014) suggests they enter conventional MHC antigen presentation pathways. The dependence on indirect antigen presentation in this assay may explain this observation. In accordance with the ELISPOT results, in a delayed-type hypersensitivity test, only mismatched mitochondria generated paw swelling, whereas isogeneic cytosol did not ( Figure 2I ). The location of the antigens for BALB/c immune activation against NT-ESCs was thus restricted to the mitochondrial fraction.
We next tested whether acquired immunological tolerance against allogeneic mitochondria can be induced. In accordance with the Medawar experiments (Billingham et al., 1953) , neonatal BALB/c mice were immunized with mitomycin-inhibited NT-ESCs ( Figure 2J ). In adulthood, these animals were re-injected with NT-ESCs (BALB/c re-inject ). In contrast to adult BALB/c recipients that received their first NT-ESC grafts, BALB/c re-inject showed no IFNγ response in ELISPOT assays and all animals developed teratomas ( Figure 2K-L) . This experiment not only shows that tolerance against allogeneic mitochondria can reliably be induced, it is also further proof for the relevance of the adaptive immune system in rejecting mitochondria-mismatched grafts.
There have been few publications on the transplantation of mitochondria-mismatched cells or tissues with conflicting results. Although prolonged hematopoietic chimerism (Lanza et al., 2005) and acceptance of cardiac and renal cell transplants (Lanza et al., 2002) in cows receiving SCNT-derived mitochondria-mismatched cells was reported, this may not guarantee universal success. Pigs rejected kidney grafts from SCNT-derived mitochondria-mismatched clones (Kwak et al., 2013) . In mice and rats, it was shown that a single non-synonymous nucleotide substitution in the mitochondrial ND1 gene or the ATPase 6 gene, respectively, generated an aberrant peptide and resulted in the loss of histocompatibility (Bhuyan et al., 1997; Davies et al., 1991; Loveland et al., 1990) . Neopeptides from human mtDNA harboring largescale frameshift deletions were recently reported to bind to MHC molecules and can be recognized by T cells from other individuals (Duvvuri et al., 2014) . Interestingly, their results further suggest that some neopeptides could bind promiscuously to both MHC class I and class II alleles, activate CD4 as well as CD8 T cells, and be recognized by CD8 memory T cells.
Aberrant mitochondrial peptides may even provoke MHC overexpression and thus amplify their immunogenicity. In both mice and humans, increased MHC class I expression in cells harboring mtDNA deletions was shown (Gu et al., 2003) . Mitochondrial peptides can thus serve as immunogens (Morse et al., 1996) and the recipient immune response may depend on the alloantigenicity of the aberrant mitochondrial protein. Although thought to be beneficial for immune surveillance and clearance of cells with mitochondrial mutations (Duvvuri et al., 2014; Gu et al., 2003) , this immune feature is potentially hazardous in the context of SCNT-derived cell transplantation.
Artificial reprograming using viral or non-viral plasmid-based approaches seems to alter the expression of a multitude of genes in induced pluripotent stem cells (iPSCs) that are differentially expressed in ESCs (de Almeida et al., 2014; Zhao et al., 2011) . Specific factors being suppressed (de Almeida et al., 2014) or overexpressed (Zhao et al., 2011) In the field of xenotransplantation, the immunity against the αGal-antigen was long considered to be the one obstacle that needed to be overcome to clear the path for subsequent clinical application. However, when αGal was knocked out, xeno-immune responses were still evident and new immune targets surfaced that previously were overshadowed by the strong αGal response (Miyata and Platt, 2003) . Similarly, when nuclear DNA is matched in SCNT-derived cells, antigenic competition (Johnson et al., 1981) (A) NT-ESCs were generated using enucleated BDF1 oocytes and isolated BALB/c fibroblast nuclei. NT-ESCs were transplanted into mitochondria-MM BALB/c, MiHA-MM BDF1, MHC-MM B6, immunodeficient NOD SCID, or combined MHC-and mitochondria-MM CBA. See also Figure S1 .
(B) Recipient-specific Th1 ELISPOT results against NT-ESCs showed significantly lower IFNγ spot frequencies for BALB/c (n=18) and BDF1 recipients (n=17) compared to B6 (n=24).
Overall, the CBA IFNγ response (n=15) was the strongest and the NOD SCID response (n=6) negligible.
(C) IL-4 (Th2) ELISPOT responses revealed similar relations among groups (BALB/c n=12, BDF1 n=17, B6 n=24, NOD SCID n=8, CBA n=10) as described in (B) for Th1 response.
(D) The NT-ESC-specific IgM antibody production after 5 days was significantly stronger in B6 (n=22) than in BALB/c (n=31) or BDF1 (n=15). No IgM antibodies against NT-ESCs were detected in NOD SCID (n=6).
(E) Isogeneic SCNT-derived BALB/c ESCs (isoESCs) were generated from BALB/c oocytes and nuclei. isoESCs were transplanted either into isogeneic BALB/c or recipients with combined mitochondria-and MiHA-MM (BDF1) or mitochondria-and MHC-MM (B6).
(F) The IFNγ ELISPOT responses against isoESC grafts were negligible in BALB/c (n=5) and significantly stronger in BDF1 (n=22) or B6 (n=6). Th1 activation in MHC-MM B6 was significantly stronger than in MiHA-MM BDF1.
(G) The isoESC-specific IL-4 ELISPOT responses were significantly stronger in BDF1 (n=23) and B6 (n=10) than in BALB/c (n=5).
(H) BALB/c nude mice received NT-ESC (mitochondria-MM) or isoESC grafts. Because of the T cell deficiency, the nude model assesses NK cell responses.
(I) The IFNγ NK cell response against NT-ESCs (n=9) was similarly low as that against isoESCs (n=8).
(J-K) Teratoma growth diagrams for NT-ESCs (J, n=5) and isoESCs (K, n=5) in BALB/c nude mice are shown. The overall teratoma development is depicted in separate adjacent graphs.
On each box in ELISPOT blots, the central mark is the median, the edges of the box are the 25th and 75th percentiles, and the whiskers extend to the most extreme data points.
MM=mismatch, * p<0.05. (H) IFNγ ELISPOT analyses show some BALB/c response against isolated NT-ESC mitochondria (NT-ESCmito, n=8), whereas no reactivity against the mitochondria-depleted NT-ESC remnants (NT-ESCcytosol, n=4) was detectable.
(I) There also was a paw swelling response in BALB/c recipients challenged with cutaneous injections of isolated NT-ESC mitochondria (n=9), but not in BALB/c challenged with the mitochondria-depleted NT-ESC remnants (n=5).
(J) One group of BALB/c mice received their first NT-ESC grafts at neonatal stage and was reinjected during adulthood (BALB/c re-inject ). The other group received NT-ESC grafts only after entering adulthood (BALB/c).
(K) In ELISPOT assays, BALB/c re-inject (n=14) showed a significantly lower IFNγ response than BALB/c (n=7).
(L) The overall teratoma development of NT-ESC grafts in BALB/c re-inject (n=27) and BALB/c animals (n=7) is presented.
On each box in ELISPOT blots, the central mark is the median, the edges of the box are the 25th and 75th percentiles, and the whiskers extend to the most extreme data points. In each scatter blot, the central mark is the median. MM=mismatch, † p<0.01. affected by variants observed in this study are highlighted. Alignments were calculated using Muscle (v3.8.31 ) (Edgar, 2004) with default parameters. For visualization, UGENE (v1.11.5) (Okonechnikov et al., 2012) was employed.
(C) BALB/c (n=10), BDF1 (n=10 for IFNγ and n=5 for IL-4), and B6 (n=10) splenocytes were stimulated with PMA and ionomycin for 24h. The IFNγ and IL-4 ELISPOT frequencies were similar among the mouse strains.
Experimental Procedures

Generation and culture of NT-ESCs and isoESCs
Somatic cell nuclear transfer (SCNT)
Oocytes from superovulated BDF1 or BALB/c mice were metaphase-II arrested and enucleated.
Nuclei from BALB/c were transferred into the enucleated oocytes to create NT-ESCs and isoESCs, respectively.
Cell culture
NT-ESCs and isoESCs were cultured on mitomycin-inhibited CF1 feeders using standard ES cell media (Gibco, Darmstadt, Germany) containing LIF (Millipore, Billerica, MA). Before in vivo cell injection and in vitro immunology experiments, NT-ESCs and isoESCs were cultured on gelatin (Millipore) without feeders using standard media containing LIF. Cell cultures were regularly screened for mycoplasma infections (Lonza, Cologne, Germany). 
Immunostaining in vitro
The mouse ESC/iPSC Characterization Kit (Applied StemCell, Sunnyvale, CA) was used to demonstrate the expression of the pluripotency markers alkaline phosphatase (AP), SSEA-1, Sox2, and Oct4. Staining was performed according to the manufacturer's protocol.
In vivo teratoma assay
Teratoma formation was observed within 4 weeks after injecting 10 7 NT-ESCs intramuscularly into NOD SCID mice and teratomas were fixed with 4% paraformaldehyde and paraffinembedded for confocal immunofluorescence and histopatholgy.
To demonstrate pluripotency using immunostainings, 5µm sections underwent heat-induced antigen retrieval with Dako antigen retrieval solution (Dako, Glostrup, Denmark) in a steamer followed by blocking with Image-iT® FX signal enhancer (Invitrogen, Carlsbad, CA 
Cell transplantation
Before transplantation, NT-ESCs and isoESCs were cultured off-feeder for 1 passage to avoid contamination with feeder cells. NT-ESCs and isoESCs were trypsinated and re-suspended in sterile saline for immunobiology experiments (10 6 cells per 80µl saline for ELISPOT, 10 7 cells per 80µl saline for DTH) and NT-ESC graft survival studies (10 6 cells per 80µl saline). Cell viability was approximately 95% as determined by trypan blue staining. Cell transplantation was performed by direct injection of cell suspensions into the right thigh muscle of recipient mice using a 27-gauge syringe.
ELISPOT assays
For uni-directional Enzyme-Linked ImmunoSpot (ELISPOT) assays, recipient splenocytes were isolated from fresh spleen 5 days after NT-ESC or isoESC injection and used as responder cells. NT-ESCs or isoESCs were mitomycin-inhibited and served as stimulator cells. 10 5 stimulator cells were incubated with 5x10 5 recipient responder splenocytes for 24h and IFNγ and IL-4 spot frequencies were automatically enumerated using an ELISPOT plate reader.
Duplicates or quadruplicates were performed in most assays.
To measure the ELISPOT response to cell compartments (mitochondria or cytosol), mitochondria were isolated from 3x10 7 NT-ESCs and served as stimulators. The remainder of the cells comprised the cytosol fraction. Successful separation of mitochondria and mitochondria-depleted cytosol was confirmed by immunoblots. Mitochondrial complex IV and GAPDH were used to confirm mitochondrial and cytosol content, respectively, and to rule out cross-contamination.
In accordance to the Medawar experiments, neonatal BALB/c mice were immunized with 10 5 mitomycin-inhibited NT-ESCs. In adulthood, the animals were re-injected with 10 6 NT-ESCs (Balb/C re-inject ) and uni-directional ELISPOT assays were performed as describe above.
Unspecifically stimulated BALB/c, BDF1, and B6 splenocytes served as ELISPOT controls. For these assays, 3x10 4 responder splenocytes were stimulated with PMA (phorbol 12-myristate 13-acetate, Sigma, 1ng/ml) and ionomycin (Sigma, 500ng/ml) for 24 h.
Delayed-type hypersensitivity response (DTH)
DTH is a rapid T cell-dependent in vivo immune response to a foreign antigen, which the host immune system has experienced in the recent past. In the sensitization phase, 2x10 6 NT-ESCs were injected subcutaneously into the flank of BALB/c mice. Seven days after sensitization, heated mitochondria or cytosol fractions, obtained from 10 6 NT-ESCs, were intradermally injected into the footpad during the challenge phase and paw swelling was measured after 24h using a digimatic micrometer (Mitutoyo, Aurora, IL). Results are demonstrated as swelling response to the antigen challenge in comparison to the PBS-injected contralateral control footpad of the animals.
NT-ESC-specific antibody assay using flow cytometry (FACS)
NT-ESC-specific mouse antibodies were detected by FACS analysis as previously described (Deuse et al., 2008) . Briefly, the serum of BALB/c, BDF1, and B6 mice 5 days after transplantation of NT-ESC grafts was incubated with NT-ESCs and the binding of antibodies was quantified. Only IgM antibodies were analyzed because of their known rapid surge within 5
